Publications
Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain.. Alzheimers Res Ther. 9(1):25.
.
2017. Multicenter Validation of an MMSE-MoCA Conversion Table.. J Am Geriatr Soc. 65(5):1067-1072.
.
2017. Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities.. J Neurosci. 37(50):12263-12271.
.
2017. Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.. Neurology. 88(19):1814-1821.
.
2017. The prevalence and biomarkers' characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database.. Alzheimers Dement (N Y). 3(1):107-113.
.
2017. Progress in transnational scientific and ethics review: Commentary on the proposal for a single North American review board for research on dementia.. Alzheimers Dement.
.
2017. Recollection and familiarity in aging individuals: Gaining insight into relationships with medial temporal lobe structural integrity.. Hippocampus. 27(6):692-701.
.
2017. Research update on Alzheimer's disease and introduction to the Expert Review of Neurotherapeutics special issue.. Expert Rev Neurother. 17(1):1-2.
.
2017. Synergistic interaction between amyloid and tau predicts the progression to dementia.. Alzheimers Dement. 13(6):644-653.
.
2017. .
2017. .
2017. Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease.. Mol Psychiatry.
.
2016. Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease? Transl Neurodegener. 5:20.
.
2016. Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada.. Can J Neurol Sci. 43(4):503-12.
.
2016. Defeating Alzheimer's disease and other dementias: a priority for European science and society.. Lancet Neurol. 15(5):455-532.
.
2016. Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment: The qualitative research phase.. Alzheimers Dement. 12(1):75-84.
.
2016. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.. J Alzheimers Dis. 51(4):1237-47.
.
2016. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.. Lancet. 388(10062):2873-2884.
.
2016. Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients.. Continuum (Minneap Minn). 22(2 Dementia):615-8.
.
2016. Hippocampus and amygdala volumes from magnetic resonance images in children: Assessing accuracy of FreeSurfer and FSL against manual segmentation.. Neuroimage. 129:1-14.
.
2016. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.. Alzheimers Dement. 12(3):292-323.
.
2016. Selective familiarity deficits in otherwise cognitively intact aging individuals with genetic risk for Alzheimer's disease.. Alzheimers Dement (Amst). 2:132-9.
.
2016. VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis.. Front Neuroinform. 10:20.
.
2016. Why has therapy development for dementia failed in the last two decades? Alzheimers Dement. 12(1):60-4.
.
2016. .
2015.